Search results for "Constipation"
First drug approved for fourth-line treatment of advanced GI stromal tumors
A new kinase inhibitor, ripretinib, is now indicated to treat adults with advanced GI stromal tumors who have previously received three or more kinase inhibitor therapies, including imatinib.
https://gastroenterology.acponline.org/archives/2020/05/22/9.htm
22 May 2020
Semaglutide showed some benefit in patients with NASH, liver fibrosis
Significantly more patients taking the glucagon-like peptide-1 receptor agonist had resolution of their nonalcoholic steatohepatitis (NASH) than those taking placebo, but rates of liver fibrosis improvement were similar between groups, an industry-funded trial found.
https://gastroenterology.acponline.org/archives/2020/11/20/1.htm
20 Nov 2020
First targeted therapy approved to treat patients with GI stromal tumors, rare mutation
A kinase inhibitor was approved to treat adults with an unresectable or metastatic gastrointestinal (GI) stromal tumor who harbor a platelet-derived growth factor receptor alpha exon 18 mutation.
https://gastroenterology.acponline.org/archives/2020/01/24/8.htm
24 Jan 2020
Spotlight on FODMAPs
Two studies published this month, a review and a randomized, placebo-controlled trial, looked at the impact of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) in patients with irritable bowel syndrome.
https://gastroenterology.acponline.org/archives/2017/06/23/5.htm
23 Jun 2017
First-line immunotherapy approved for certain patients with colorectal cancer
Pembrolizumab (Keytruda) for IV injection is now indicated to treat patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
https://gastroenterology.acponline.org/archives/2020/07/24/8.htm
24 Jul 2020
Use of drugs, nondrug treatments for functional bowel disorders analyzed
One study found that nonpharmacologic interventions are underused in ambulatory care visits for functional bowel disorders, while another found that patients with irritable bowel disease and their insurers have financial incentives to favor differing treatments.
https://gastroenterology.acponline.org/archives/2020/10/23/1.htm
23 Oct 2020
Efficacy, safety of second-line therapies analyzed for two types of IBS
A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
https://gastroenterology.acponline.org/archives/2019/04/26/2.htm
26 Apr 2019
FDA approves new drug for travelers' diarrhea
Compared to placebo, the drug significantly reduced symptoms in a randomized controlled trial of 264 adults with travelers' diarrhea in Guatemala and Mexico.
https://gastroenterology.acponline.org/archives/2018/11/27/6.htm
27 Nov 2018
In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months
While fecal microbiota transplantation was effective in patients with moderate to severe irritable bowel syndrome in a randomized trial, long-term risks of the therapy remain uncertain, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/05/22/10.htm
22 May 2020
Guidance issued on evaluation, treatment of hemorrhoids
Primary first-line therapy for patients with symptomatic hemorrhoid disease should typically include dietary modification to ensure adequate fluid and fiber intake and counseling on defecation habits, the guidelines said.
https://gastroenterology.acponline.org/archives/2018/03/23/8.htm
23 Mar 2018